share_log

Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43

Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43

Canaccord Genuity維持對Cartesian Therapeutics的買入評級,並將目標價提高至43美元。
Benzinga ·  07/03 10:23

Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $38 to $43.

Canaccord Genuity分析師約翰·紐曼認爲,Cartesian Therapeutics (納斯達克股票代碼:RNAC) 值得買入,並將目標價從38美元升至43美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論